Futura Medical PLC Clinical trial data presented at SMSNA

RNS Number : 4942I

Futura Medical PLC

17 October 2024

 

17 October 2024                                   

Futura Medical plc

("Futura", "the Group" or the "Company")

Clinical trial data presented at SMSNA

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon^®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that three abstracts on MED3000 are being presented at the Sexual Medicine Society of North America (SMSNA) at their annual conference in Scottsdale, Arizona on 17^th to 20^th October. The SMSNA promotes, encourages, and supports the highest standards of practice, research, education, and ethics in the study of human sexual function and dysfunction.

 

The abstracts detail the results of clinical trials, showing the positive impact of MED3000 on Erectile Dysfunction (ED) but also self-esteem and relationships in men with ED and sexual encounter profiles for men and their partners.

 

The importance of the presentation of these abstracts is to educate and improve awareness amongst key opinion leaders and other healthcare practitioners about the benefits of MED3000 (now available through the USA under the brand name Eroxon^®) as a clinical proven treatment for ED.

 

Details of the of the abstracts, methods and results can be found at: https://www.smsna.org/annual2024/program

 

Abstract 1	Topical Administration of MED3000 Gel Significantly Improves Self-esteem and Relationships in Men with Erectile Dysfunction: Results from Two Clinical Trials
Abstract 2	Topical Administration of MED3000 Gel Significantly Improves Erectile Function in Men with Mild, Moderate, or Severe Erectile Dysfunction: Results from Two Multicenter Clinical Trials
Abstract 3	Topical Administration of MED3000 Gel Significantly Improves All Aspects of the Sexual Encounter Profile for Both Men and Their Partners

 

The abstracts are presented to the audience and then all abstracts presented at the meeting will be published in a supplement of the Journal of Sexual Medicine.

 

 

Contacts:

Futura Medical plc	James Barder Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Stifel Nicolaus Europe Limited Joint Broker	Alan Selby Ben Maddison	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock	[phone] [e-mail]

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABLBDGLBBDGSL